Three simple steps: a guidelines-based approach to global CVD risk stratification that’s as easy as 1-2-3
- Test – Order a VAP+ Lipid Panel for your initial assessment
- Assess – stratify patient risk
- The most accurate and comprehensive cholesterol test to comply with National Cholesterol Education Program ATP III recommendations 12 for direct LDLc measurement and secondary and emerging risk factors
- The only commercially available test that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association, American College of Cardiology guidelines13, and American Association of Clinical Endocrinologists 17
- The test of choice for accurate, global cardiometabolic risk stratification and management
- Treat – Personalize treatment strategy to improve outcomes
The basic cholesterol test misclassifies risk
Very Large Database of Lipids (VLDL)
In 1.3 million patients, Friedewald (estimated) LDLc consistently underestimates LDLc, resulting in undertreatment of high-risk patients.
Intermountain Heart Collaborative Study
A large percentage of heart disease patients remain at high residual risk despite having achieved basic cholesterol test target LDLc treatment goals.
Healthy, Middle-aged Patients
Low HDL2c reveals cardiovascular risk in six times as many patients as the basic cholesterol test.
HDLc subclass is an independent risk factor
Framingham Heart Study Cohort
Increased HDLc revealed a 40% lower risk for 3 coronary heart disease (CHD) and 36% lower risk for Hard CHD.
Low HDL3c revealed a 50% mortality risk for secondary prevention.
Jackson Heart Study
Increased HDL3c revealed a 68% lower risk for Hard CHD and a 35% lower risk for CHD.
Remnant lipoproteins predict heart attack risk
Jackson Heart Study
Elevated remnant lipoproteins are 28% more likely to reveal a significant, independent risk factor for heart attack.
Framingham Heart Study
Remnant lipoproteins were an independent risk factor for incident CHD events.
Framingham Heart Study
Pattern B revealed double the risk for Hard CHD and a 40% increased risk for CHD.
Clinical Trial Sub
Analysis of patients involved in the pomegranate consumption trial showed that LDLc Pattern B predicts carotid intima media thickness (CIMT) and CHD progression.
VAP Lipid Panel improves outcomes and reduces cost
VAP Lipid Panel and personalized lipid treatment improved patient outcomes and reduced healthcare costs by 35%.
Effective Disease Management: A two-year, retrospective cohort study of individuals diagnosed with CVD14,15:
Improved Patient Outcomes
- The study enrolled a total of 1,767 patients (cases) diagnosed with cardiovascular disease.14,15
- Use of the VAP Lipid Panel permitted WellMed to detect more cases of dyslipidemia than the BLP, enabling more appropriate and effective therapy to be prescribed and ultimately leading to better outcomes.14,15
- Those tested with the VAP Lipid Panel had lower total costs in year two ($4,852.62 vs. $7,413.18), fewer total inpatient stays (13.1% vs. 18.3% of controls), and fewer total emergency department visits (11.9% vs. 15.6% of controls).14,15
Reduced costs to managed care by 35%
- Increased frequency of monitoring with the VAP Lipid Panel, combined with therapy adjustments, led to lower LDLc and higher HDL3 levels. HDL2 also improved, but this was not correlated with the number of VAP Lipid Panel panels given.14,15
- Significant savings can be achieved through the use of a comprehensive cholesterol test, like the VAP Lipid Panel, in tandem with treatment regimens based on the various lipid components identified.14,15
THE W.I.S.E STUDY
BASIC CHOLESTEROL TEST CONSISTENTLY UNDERESTIMATES LDLC
More evidence supporting the VAP Lipid Panel was published in the Journal of the American College of Cardiology. Clinical findings from the study, which compared the accuracy of VAP Lipid Panel directly measured LDLc to basic cholesterol test estimated LDLc, include:
- Basic cholesterol test (calculated) LDL consistently underestimates LDL, resulting in undertreatment of high-risk patients. This underestimation was found to be by as much as 60% in patients with triglycerides 200- 399 mg/dL as compared to VAP Lipid Panel directly measured LDLc.
- Even in patients with normal triglyceride levels (<150 mg/dL, or about 70% of the adult U.S. population), previous research indicates 10-20% of such patients would be reclassified into a higher risk category using direct LDLc measurement.16
- The VAP Lipid Panel is the only cholesterol analysis that directly measures cholesterol concentrations using density gradient ultracentrifugation to provide more accurate risk assessment and monitoring of atherosclerosis in patients.
- Accurate risk assessment allows for more targeted, personalized treatment strategies, and ultimately better patient outcomes.
As a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, we offer researchers a number of unique and valuable analytical research tools, including the VAP+ Lipid Panel®.
Here, every research study is carefully planned and conducted to accommodate the needs and expectations of our clients and study sponsors. Leading institutions and research organizations regularly depend on us to meet their study deadlines, while upholding the highest standards of clinical excellence and data integrity.
Because of the sophistication of the VAP+ Lipid Panel and its accuracy when compared with the basic cholesterol test, it is used in current clinical research for the testing of both human and animal specimens, fresh or frozen (-70F) specimens, and serum or plasma specimens.
VAP+ technology has been chosen for the analysis of millions of clinical research specimens from a variety of studies. The list below highlights of some of the studies in which the VAP+ Lipid Panel has been used. We also have a full list of studies available.
Jackson Heart Study
Emory Estrogen Vascular Study
Johns Hopkins Sibling Study
Intermountain Heart Study
Fibercel Pilot Trial
Native American CHD Risk Factor Study
AstraZeneca Rosuvastatin Study
Yale Pathophysiology of Type 2 Diabetes in Youth Study
Our Vice President of Research and Development
KRIS KULKARNI, PH.D.
has been in charge of Research and Development since 1999, specializing in testing CV risk markers. Prior to joining Atherotech, Dr. Kulkarni was with the Department of Medicine at the University of Alabama at Birmingham for 12 years. He began his career as a postdoctoral fellow, rising to the position of Research Assistant Professor of Medicine. He was involved in every phase of the development of the VAP+ Lipid Panel. Dr. Kulkarni is a member of the American Association of Clinical Chemistry (AACC) and has published extensively.
Our Healthy Heart®
Provides patients with personalized lifestyle modification education, compliance strategies, and coaching from personal clinical health coaches at no additional cost
An award-winning blog established to share patient cases and educate on diagnosis and treatment management of cardiovascular conditions
Medical Science Consultants
Help with interpreting VAP+ results and information regarding risk factor identification, clinical implications, and treatment options